Spots Global Cancer Trial Database for ponatinib
Every month we try and update this database with for ponatinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL) | NCT01207440 | Chronic Myeloid... Ph+ Acute Lymph... | Ponatinib | 18 Years - | Takeda | |
| Ponatinib in Adult Ph+ ALL Patients With MRD Positivity or Hematological Relapse | NCT04475731 | Philadelphia-Po... Acute Lymphobla... | Ponatinib | 18 Years - | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia | NCT05268003 | Acute Lymphobla... Leukemia | Ponatinib Venetoclax Mini-hyper CVD | 12 Years - | M.D. Anderson Cancer Center | |
| Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients | NCT05306301 | Chemotherapy Leukemia, Acute... | Ponatinib | 18 Years - 65 Years | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| A Phase 2 Trial of Ponatinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor | NCT01874665 | GIST | Ponatinib | 18 Years - | Takeda | |
| Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT | NCT06061094 | Philadelphia Ch... | Imatinib Ponatinib Blinatumomab Indication for ... | 18 Years - 65 Years | Goethe University | |
| A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia | NCT05268003 | Acute Lymphobla... Leukemia | Ponatinib Venetoclax Mini-hyper CVD | 12 Years - | M.D. Anderson Cancer Center | |
| Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT | NCT06061094 | Philadelphia Ch... | Imatinib Ponatinib Blinatumomab Indication for ... | 18 Years - 65 Years | Goethe University | |
| Ponatinib With Chemotherapy for Young Adults Ph Positive Acute Lymphoblastic Leukemia | NCT02776605 | ALL | Prednisone Vincristine Daunorubicin Prednisone Ponatinib Mercaptopurine Methotrexate VP-16 ARA-C: TIT Ponatinib Autologous tran... Allo transplant... | 18 Years - 55 Years | PETHEMA Foundation | |
| Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML) | NCT02829840 | Leukemia FLT3-Mutated Ac... FLT3-Mutated Hi... | Ponatinib 5-azacytidine Phone Calls | 18 Years - | M.D. Anderson Cancer Center | |
| Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to Imatinib | NCT02398825 | Chronic Myeloid... Chronic Phase Adults | Ponatinib | 18 Years - | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP) | NCT01570868 | Leukemia | Ponatinib | 18 Years - | M.D. Anderson Cancer Center | |
| Iclusig® (Ponatinib) in Clinical Practice for the Treatment of Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia in Belgium | NCT03678454 | Chronic Myeloid... CML Philadelphia Ch... Ph+ ALL | 18 Years - | Incyte Corporation | ||
| Safety and Efficacy of Ponatinib Followed by Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase | NCT04070443 | Philadelphia Ch... BCR-ABL Positiv... | Ponatinib Imatinib | 18 Years - 65 Years | Centre Leon Berard | |
| Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia | NCT03263572 | Accelerated Pha... Acute Lymphobla... BCR-ABL1 Fusion... Blast Phase Chr... Philadelphia Ch... Recurrent Acute... Refractory Acut... t(9;22) | Blinatumomab Cytarabine Methotrexate Ponatinib | 18 Years - | M.D. Anderson Cancer Center | |
| Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to Imatinib | NCT02398825 | Chronic Myeloid... Chronic Phase Adults | Ponatinib | 18 Years - | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation | NCT04233346 | Chronic Myeloid... Acute Lymphobla... | Ponatinib | 18 Years - | Otsuka Beijing Research Institute | |
| Study to Evaluate the Reinduction and Second Stop of TKI With Ponatinib in CML in Molecular Response (ResToP) | NCT04160546 | Chronic Myeloid... | Ponatinib 15 MG Acetylsalicylic... | 18 Years - | Fundacion CRIS de Investigación para Vencer el Cáncer | |
| Ponatinib for Advanced Medullary Thyroid Cancer | NCT01838642 | Thyroid Neoplas... | Ponatinib | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Ponatinib With Chemotherapy for Young Adults Ph Positive Acute Lymphoblastic Leukemia | NCT02776605 | ALL | Prednisone Vincristine Daunorubicin Prednisone Ponatinib Mercaptopurine Methotrexate VP-16 ARA-C: TIT Ponatinib Autologous tran... Allo transplant... | 18 Years - 55 Years | PETHEMA Foundation | |
| Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses | NCT02467270 | Myeloid Leukemi... | Ponatinib | 18 Years - | Takeda | |
| Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients | NCT05306301 | Chemotherapy Leukemia, Acute... | Ponatinib | 18 Years - 65 Years | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia | NCT03589326 | Philadelphia Ch... | Ponatinib Imatinib Vincristine Dexamethasone Cytarabine Methotrexate Prednisone | 18 Years - | Takeda | |
| Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database | NCT05286528 | Chronic Myeloid... | Bosutinib Imatinib Nilotinib Dasatinib Ponatinib | - | Pfizer | |
| An Observational Registry to Evaluate the Incidence of and Risk Factors for Vascular Occlusive Events Associated With ICLUSIG® | NCT02455024 | Myeloid Leukemi... | 18 Years - | Takeda | ||
| Expanded Access Program of Ponatinib | NCT01592136 | Chronic Myeloid... Philadelphia Ch... | ponatinib | 18 Years - | Takeda | |
| Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers | NCT01935336 | Adenocarcinoma ... Extensive Stage... Limited Stage S... Recurrent Non-s... Recurrent Small... Stage IIIA Non-... Stage IIIB Non-... Stage IV Non-sm... | Ponatinib | 18 Years - | University of Colorado, Denver | |
| Ponatinib for Squamous Cell Lung and Head and Neck Cancers | NCT01761747 | Non-Small Cell ... | ponatinib | 18 Years - | Dana-Farber Cancer Institute | |
| PONAZA : A COMBINATION OF PONATINIB AND 5-AZACITIDINE IN CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE OR IN MYELOID BLAST CRISIS | NCT03895671 | CHRONIC MYELOGE... CHRONIC MYELOGE... | Ponatinib Azacitidine | 18 Years - | Versailles Hospital | |
| The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP | NCT06390306 | Chronic Myeloid... | Ponatinib Azacitidine Venetoclax Olverembatinib | 18 Years - | Peking University People's Hospital | |
| The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP | NCT06390306 | Chronic Myeloid... | Ponatinib Azacitidine Venetoclax Olverembatinib | 18 Years - | Peking University People's Hospital | |
| An Observational Registry to Evaluate the Incidence of and Risk Factors for Vascular Occlusive Events Associated With ICLUSIG® | NCT02455024 | Myeloid Leukemi... | 18 Years - | Takeda | ||
| Ponatinib for Advanced Medullary Thyroid Cancer | NCT01838642 | Thyroid Neoplas... | Ponatinib | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Study in Adult Ph-positive ALL | NCT04688983 | Acute Lymphobla... | Ponatinib Blinatumomab Imatinib | 55 Years - | Cardiff University | |
| Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma | NCT02478164 | Glioblastoma | Ponatinib | 18 Years - | Dana-Farber Cancer Institute | |
| Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers | NCT01935336 | Adenocarcinoma ... Extensive Stage... Limited Stage S... Recurrent Non-s... Recurrent Small... Stage IIIA Non-... Stage IIIB Non-... Stage IV Non-sm... | Ponatinib | 18 Years - | University of Colorado, Denver | |
| Study in Patients With Chronic Leukemia | NCT03807479 | Leukemia, Myelo... | Ponatinib | 18 Years - | GWT-TUD GmbH | |
| Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia | NCT03263572 | Accelerated Pha... Acute Lymphobla... BCR-ABL1 Fusion... Blast Phase Chr... Philadelphia Ch... Recurrent Acute... Refractory Acut... t(9;22) | Blinatumomab Cytarabine Methotrexate Ponatinib | 18 Years - | M.D. Anderson Cancer Center | |
| Ponatinib in the Treatment of FGFR Mutation Positive Recurrent or Persistent Endometrial Carcinoma | NCT01888562 | Endometrial Neo... | Ponatinib | 18 Years - | Washington University School of Medicine | |
| Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP) | NCT01570868 | Leukemia | Ponatinib | 18 Years - | M.D. Anderson Cancer Center | |
| Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer | NCT03838692 | Medullary Thyro... | Ponatinib | 18 Years - | Columbia University | |
| Ponatinib in CML Patients in Chronic Phase | NCT06119269 | Chronic Myeloid... | Therapeutic dru... Molecular Respo... | 18 Years - | University of Pisa | |
| Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors | NCT03934372 | Acute Myeloid L... Accelerated Pha... Blast Phase Chr... Chronic Phase C... Acute Lymphobla... Acute Lymphocyt... Leukemia Lymphoma Solid Tumors | Ponatinib | 1 Year - 17 Years | Incyte Corporation | |
| Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia | NCT04188405 | Accelerated Pha... Acute Myeloid L... Blast Phase Chr... Recurrent Acute... Recurrent Chron... Refractory Acut... Refractory Chro... | Decitabine Ponatinib Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL) | NCT01207440 | Chronic Myeloid... Ph+ Acute Lymph... | Ponatinib | 18 Years - | Takeda | |
| Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer | NCT03704688 | Non Small Cell ... KRAS Gene Mutat... | Trametinib 0.5 ... Trametinib 1 MG Trametinib 1.5 ... Trametinib 2 mg Ponatinib 15 MG Ponatinib 30 MG | 19 Years - | Memorial Sloan Kettering Cancer Center | |
| Consolidation Treatment With Ponatinib 15 mg on Treatment Free-Remission Rate in Patients With Chronic Myeloid Leukemia | NCT04043676 | Chronic Myeloid... | Ponatinib | 18 Years - | Fundación Teófilo Hernando, Spain | |
| Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer | NCT03838692 | Medullary Thyro... | Ponatinib | 18 Years - | Columbia University | |
| Safety and Efficacy of Ponatinib Followed by Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase | NCT04070443 | Philadelphia Ch... BCR-ABL Positiv... | Ponatinib Imatinib | 18 Years - 65 Years | Centre Leon Berard | |
| Ponatinib in the Treatment of FGFR Mutation Positive Recurrent or Persistent Endometrial Carcinoma | NCT01888562 | Endometrial Neo... | Ponatinib | 18 Years - | Washington University School of Medicine | |
| Treatment Protocol for Newky Diagnosed Adult Ph Positive ALL | NCT06175702 | Lymphoblastic L... Philadelphia-Po... Adult ALL | Vincristine Dexamethasone Imatinib Cytarabine Mercaptopurine Methotrexate Ponatinib allogeneic stem... Total body irra... Cyclophosphamid... Fludarabine | 18 Years - | PETHEMA Foundation | |
| The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy | NCT04591431 | Breast Cancer Gastrointestina... Non Small Cell ... Other Cancer | Erlotinib Trastuzumab Trastuzumab emt... Pertuzumab Lapatinib Everolimus Vemurafenib Cobimetinib Alectinib Brigatinib Palbociclib Ponatinib Vismogedib Itacitinib Ipatasertib Entrectinib Atezolizumab Nivolumab Ipilimumab Pemigatinib Oncology Drugs Pralsetinib Selpercatinib Talazoparib Tepotinib Alpelisib | 18 Years - | Fondazione per la Medicina Personalizzata | |
| POETIG Trial - POnatinib After rEsisTance to Imatinib in GIST | NCT03171389 | GIST, Malignant KIT Exon 13 Mut... KIT Gene Mutati... | Ponatinib 30 MG | 18 Years - | Universität Duisburg-Essen | |
| POETIG Trial - POnatinib After rEsisTance to Imatinib in GIST | NCT03171389 | GIST, Malignant KIT Exon 13 Mut... KIT Gene Mutati... | Ponatinib 30 MG | 18 Years - | Universität Duisburg-Essen | |
| Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients | NCT05306301 | Chemotherapy Leukemia, Acute... | Ponatinib | 18 Years - 65 Years | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| Ponatinib in Advanced NSCLC w/ RET Translocations | NCT01813734 | Non Small Cell ... | Ponatinib | 18 Years - | Massachusetts General Hospital | |
| Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database | NCT05286528 | Chronic Myeloid... | Bosutinib Imatinib Nilotinib Dasatinib Ponatinib | - | Pfizer | |
| Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological Malignancies | NCT00660920 | Chronic Myeloge... Hematologic Mal... | Ponatinib | 18 Years - | Takeda | |
| Ponatinib in CML Patients in Chronic Phase | NCT06119269 | Chronic Myeloid... | Therapeutic dru... Molecular Respo... | 18 Years - | University of Pisa | |
| Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP) | NCT01570868 | Leukemia | Ponatinib | 18 Years - | M.D. Anderson Cancer Center | |
| An Observational Registry to Evaluate the Incidence of and Risk Factors for Vascular Occlusive Events Associated With ICLUSIG® | NCT02455024 | Myeloid Leukemi... | 18 Years - | Takeda | ||
| The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation | NCT04233346 | Chronic Myeloid... Acute Lymphobla... | Ponatinib | 18 Years - | Otsuka Beijing Research Institute | |
| Expanded Access Program of Ponatinib | NCT01592136 | Chronic Myeloid... Philadelphia Ch... | ponatinib | 18 Years - | Takeda | |
| Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML) | NCT02829840 | Leukemia FLT3-Mutated Ac... FLT3-Mutated Hi... | Ponatinib 5-azacytidine Phone Calls | 18 Years - | M.D. Anderson Cancer Center | |
| Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to Imatinib | NCT02398825 | Chronic Myeloid... Chronic Phase Adults | Ponatinib | 18 Years - | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| A Study to Evaluate Effectiveness and Safety of Ponatinib in Patients With BCR-ABL Positive ALL in Standard Clinical Practice in Europe - "POSEIDON" | NCT03515785 | BCR-ABL Positiv... | 18 Years - | Incyte Corporation | ||
| Compassionate Use Ponatinib | NCT01549548 | Philadelphia Ch... Chronic Myeloid... | Ponatinib | 18 Years - | OHSU Knight Cancer Institute | |
| Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia | NCT01424982 | Accelerated Pha... Acute Lymphobla... Adult Acute Lym... B Acute Lymphob... Blast Phase Chr... Philadelphia Ch... Untreated Adult... | Cyclophosphamid... Cytarabine Dexamethasone Doxorubicin Doxorubicin Hyd... Laboratory Biom... Methotrexate Ponatinib Ponatinib Hydro... Prednisone Rituximab Vincristine Vincristine Sul... | 18 Years - | M.D. Anderson Cancer Center | |
| Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients | NCT05306301 | Chemotherapy Leukemia, Acute... | Ponatinib | 18 Years - 65 Years | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| Iclusig® (Ponatinib) in Clinical Practice for the Treatment of Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia in Belgium | NCT03678454 | Chronic Myeloid... CML Philadelphia Ch... Ph+ ALL | 18 Years - | Incyte Corporation | ||
| Phase II Front-line Ponatinib in Adult Philadelphia+/BCR-ABL+ Acute Lymphoblastic Leukemia. | NCT01641107 | Philadelphia Po... BCR-ABL Positiv... Acute Lymphobla... | Ponatinib | 18 Years - | Incyte Corporation |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
